HoneyNaps Receives FDA 510(k) Clearance for AI Software SOMNUM V3.0 for Subtype-Specific Sleep Apnea Classification

July 26, 2026

Sleep Review USA

Overview

HoneyNaps, a South Korean company, announced that its AI diagnostic software, SOMNUM V3.0, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The software automatically detects and classifies obstructive, central, and mixed sleep apnea from polysomnography (PSG) data, aiming to enhance diagnostic accuracy and efficiency. This approval is expected to improve the workflow for sleep technicians and support the development of next-generation digital biomarkers for sleep-disordered breathing.

In Depth

Key Findings

HoneyNaps’ AI-powered diagnostic software, SOMNUM V3.0, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This groundbreaking software is designed to automatically detect and classify specific subtypes of sleep apnea—obstructive, central, and mixed—by analyzing polysomnography (PSG) data, marking a significant advancement in sleep medicine diagnostics.

Technical & Clinical Details

Automated Subtype Classification: SOMNUM V3.0 leverages advanced AI algorithms to process complex PSG data, providing an automated and objective method for differentiating sleep apnea subtypes. Traditionally, this classification heavily relies on the expertise and subjective interpretation of sleep specialists, which can lead to variability.
Enhanced Diagnostic Efficiency: By automating the analysis process, the software is expected to reduce the time burden on sleep technologists, allowing for more streamlined workflows and potentially increasing patient access to timely diagnoses.
Support for Digital Biomarker Development: The granular data analysis capabilities of SOMNUM V3.0 pave the way for identifying novel digital biomarkers associated with sleep-disordered breathing. This foundational work could accelerate personalized treatment strategies and contribute to precision medicine in sleep disorders.

Background & Industry Context

Sleep apnea is a prevalent condition linked to serious comorbidities such as cardiovascular disease, diabetes, and stroke, underscoring the importance of accurate and early diagnosis. However, the diagnostic pathway often involves lengthy wait times and relies on highly specialized interpretation. AI-driven solutions like SOMNUM V3.0 address these bottlenecks by offering a scalable, consistent, and objective diagnostic aid. This FDA clearance highlights the accelerating trend of AI integration into digital health, transforming clinical practice and patient care across various medical specialties.

Future Outlook

With this FDA clearance, HoneyNaps is poised to expand its market presence in the U.S., a key region for medical device innovation. The widespread adoption of SOMNUM V3.0 could significantly impact the diagnostic landscape for sleep apnea, improving patient outcomes through earlier and more precise interventions. Furthermore, the rich dataset generated by the software will serve as a valuable resource for ongoing research into sleep disorders, potentially leading to new insights for prevention and therapeutic development.

Source: https://sleepreviewmag.com/sleep-diagnostics/connected-care/ai-machine-learning/fda-clears-somnumv30/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.